Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Wipro Limited — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Wipro Limited trades at $1.79 (market cap $17.45B). The key difference: Wipro Limited is far larger — about 3.6× Travere Therapeutics Inc. Common Stock's market cap, and Wipro Limited pays a 4.82% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Wipro Limited for 41 Days on average.
| TVTX | WIT | |
|---|---|---|
Market Cap | $4.88B | $17.45B |
Volume | 1,668,577 | 12,096,194 |
Sector | Health | Technology |
52-Week High | $67.52 | $3.06 |
52-Week Low | $26.79 | $1.61 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $5.01B | $15.54B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Wipro (WIT) trades at $1.80, up 5.88% with a bullish technical signal. The company maintains solid fundamentals with $890.88B revenue, 13.92% net margin, and $131.35B net income for 2025. Recent AI initiatives have boosted productivity equivalent to 20,000 employees. However, the stock faces mixed analyst sentiment with only 19% buy ratings and recent earnings misses.
Wipro presents a mixed investment case with reasonable valuation (P/E 13.84) and strong cash flow generation offset by earnings volatility and competitive pressures. The AI transformation offers growth potential, but investors should weigh execution risks against the company's established market position and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
